Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:09 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Diazoxide Suppression Test P&F Study
NCT06606327 · Columbia University · PHASE1 · terminated · last registry update 2026-08-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Reprioritization of research efforts” | – | Registry record, Columbia University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against KCNJ11 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-02Also stopped (withdrawn): Applied Biology, Inc., Topical minoxidil 5% + DA-002 (NCT06501924)
- 2026-10-19Results posted on the registry: DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, DC-806 + Midazolam (NCT06092931)
- 2026-10-13Also stopped (withdrawn): Soleno Therapeutics, Inc., DCCR (diazoxide choline) extended-release tablets (NCT05532020)
- 2026-09-30Results posted on the registry: Columbia University, Diazoxide oral suspension, 1 mg per kg per dose + Diazoxide oral suspension, 2 mg per kg per dose (NCT05729282)
- 2026-08-31Results posted on the registry: Michael Hoelscher, BTZ-043 + Rifafour e-275® (NCT04044001)
- 2026-05-22Results posted on the registry: Boehringer Ingelheim, BI 1569912 + Repaglinide (NCT06367153)
- 2026-04-14Phase 3 first posted: Eurofarma Laboratorios S.A., Minoxidil oral solution + Placebo oral solution (NCT07529977)
- 2026-02-27Phase 3 first posted: Triple Hair Inc, TH07 + TH07 (NCT07435012)
- 2025-12-12Results posted on the registry: Eli Lilly and Company, Imlunestrant + Repaglinide (NCT05444556)
- 2025-12-11Results posted on the registry: Eli Lilly and Company, Repaglinide + Selpercatinib (NCT05469113)
- 2025-12-10Phase 3 first posted: Sheikh Zayed Federal Postgraduate Medical Institute, Minoxidil 5 % Topical Spray + minoxidil (NCT07273799)
- 2025-12-02Results posted on the registry: Boehringer Ingelheim, zongertinib + midazolam (NCT06494761)
- 2025-09-11Results posted on the registry: Albert Einstein College of Medicine, Naloxone + Diazoxide (NCT03608163)
- 2025-09-11Also stopped (terminated): Albert Einstein College of Medicine, Naloxone + Diazoxide (NCT03608163)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision